Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis

1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55-67.10.1007/s13311-012-0147-4Search in Google Scholar

2. Krueger JG, Kircik L, Hougeir F, et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther. 2016;33:1231-1245.10.1007/s12325-016-0353-2Search in Google Scholar

3. Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847-855.10.1212/WNL.0000000000002417Search in Google Scholar

4. Kircik L, Krueger J, Lebwohl M, et al. Incidence, severity, duration, and treatment of cutaneous adverse events in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a in patients with relapsingremitting multiple sclerosis. Mult Scler. 2015;21:251-252.Search in Google Scholar

5. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167-2175.10.1016/S0140-6736(12)62190-4Search in Google Scholar

6. Diao L, Hang Y, Othman AA, et al. Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol. 2016;82:1333-1342.10.1111/bcp.13051506179427333593Search in Google Scholar

7. Michel T, Poli A, Cuapio A et al. Human CD56bright NK Cells: An Update. J Immunol. 2016; 196:2923-2931.10.4049/jimmunol.150257026994304Search in Google Scholar